Blog > Ripjar Placed as a Name Screening Category Leader in Chartis Quadrant

Corporate


Ripjar Placed as a Name Screening Category Leader in Chartis Quadrant

We’re proud to share that Ripjar has been recognised as a category leader in the 2022 Chartis RiskTech Quadrant for Name Screening.

Chartis Research is the leading provider of research and analysis for the global risk technology market. As part of their mission to provide in-depth analysis and advice on all aspects of risk technology, they produce reports on watchlist screening and monitoring solutions, including name screening.

The name screening segment considers a number of criteria, including each solution’s ability to handle naming convention challenges, enrich data with additional information, screen large data volumes, and its speed and efficiency. 

Solutions are assessed on the completeness of their offering and their market potential. Scoring highly in both areas, Ripjar has been ranked as a category leader.

“Ripjar’s innovative approach to solving real market challenges, based on advanced technology and analytics capabilities, makes it an exciting player in the name screening space,” said Nick Vitchev, Research Director at Chartis. “Its focus on tackling highly complex client challenges with an effective tech-first approach is reflected in its category leader status in Chartis’ 2022 name screening quadrant.”

About Ripjar’s Labyrinth Screening Platform

With global events resulting in a rapidly-evolving sanctions environment, and regulatory compliance increasingly requiring adverse media screening, comprehensive name screening is more important than ever. 

The latest release of Ripjar’s Labyrinth Screening platform includes innovative new AI Risk Profiles. This feature enables organisations to screen across vast amounts of structured and unstructured data with increased accuracy, efficiency and effectiveness. It reviews sanctions list, watchlist, PEP and adverse media data to build enriched, discrete profiles for individuals and organisations, reducing false positives and significantly reducing analyst workloads. 


Learn more about Ripjar’s adverse media screening

Subscribe to Newsletter

Ask us for a demonstration that will transform your data intelligence strategy.